A combination antibody treatment for Covid-19 has met its primary endpoint of improving  survival in patients hospitalised with the disease, the developer Regeneron Pharmaceuticals Inc announced on 16 June. The treatment, REGEN-COV, is a combination of the monoclonal antibodies casirivimab and imdevimab, which are both investigational compounds. The US Food and Drug Administration has given the combination treatment an emergency use authorisation.

Stratatech Corp, a unit of Dublin, Ireland-based Mallinckrodt Plc, has received regulatory approval in the US for its treatment for thermal burns. The treatment, StrataGraft, is produced from two types of human skin cells, keratinocytes and dermal fibroblasts, which have been grown together to make a cellularised scaffold. It is a topical treatment, to be placed onto the burn by a healthcare provider.